RT Journal Article
T1 Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract
A1 Torres-Cornejo, A.
A1 BenMarzouk-Hidalgo, O. J.
A1 Viciana, P.
A1 Sanchez, B.
A1 Lopez-Ruz, M. A.
A1 Lopez-Cortes, L. F.
A1 Gutierrez-Valencia, A.
K1 Human immunodeficiency virus 1 infection
K1 human immunodeficiency virus 1 treatment
K1 male genital tract
K1 protease inhibitor monotherapy
K1 triple therapy
K1 Viral load
K1 Blood-plasma
K1 Hiv-1 rna
K1 Semen
K1 Lopinavir/ritonavir
K1 Men
K1 Ritonavir
AB Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT. (C)2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
PB Elsevier sci ltd
SN 1198-743X
YR 2016
FD 2016-01-01
LK http://hdl.handle.net/10668/18746
UL http://hdl.handle.net/10668/18746
LA en
DS RISalud
RD Apr 15, 2025